Sells the only two FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome.
What stands out
- Earnings significantly exceed cash generation
At a glance
Sells the only two FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome.
Acadia Pharmaceuticals sells the only two drugs the FDA has approved for Parkinson's disease psychosis and Rett syndrome — pimavanserin under the brand NUPLAZID and trofinetide under DAYBUE — which means neurologists treating those conditions must prescribe through Acadia or prescribe nothing that carries regulatory approval. Because no competing drug holds either approval, Acadia's revenue is not determined by winning market share but by how many patients within each small, defined population are diagnosed and treated at all. The main thing that could end that position is not a competitor arriving with a better drug — replicating either approval requires years of clinical trials and a separate FDA review with no guaranteed outcome — but rather the FDA withdrawing or restricting one of the existing approvals due to a post-market safety finding, or a manufacturing facility failing an inspection and cutting off the only approved supply those patients have.
How does this company make money?
The company earns money each time a prescription of NUPLAZID tablets or DAYBUE oral solution is filled through a specialty pharmacy. Revenue is the number of prescriptions multiplied by the price negotiated with insurance companies and pharmacy benefit managers. Because both drugs treat rare conditions and have no approved competitors, the negotiated prices are high — but getting each prescription covered still requires insurance approval, so reimbursement decisions directly shape how many patients can access the drugs and how much the company collects.
What makes this company hard to replace?
Neurologists who prescribe NUPLAZID or DAYBUE must complete prior authorization processes and set up patient monitoring routines that are specific to each drug — none of that work transfers to a different treatment. Rett syndrome patients and their families learn the specific dose titration schedules and the liquid formulation of DAYBUE, and switching would mean starting that learning process over from scratch. Specialty pharmacies have also built their inventory systems and distribution workflows around these specific drugs, which makes substituting another product operationally disruptive even if one existed.
What limits this company?
The factories that make NUPLAZID and DAYBUE must continuously pass FDA inspections. If inspectors found a serious problem and halted production at either facility, there would be no approved backup drug to fill the gap — patients who depend on that medicine would simply go without. Supply cannot be shifted to a competitor; it disappears entirely until the facility problem is resolved.
What does this company depend on?
The company cannot operate without five things: FDA-validated manufacturing approvals for the facilities that produce NUPLAZID and DAYBUE; the raw ingredient supply chains used to synthesize pimavanserin and trofinetide; specialty pharmacy networks that manage the prior authorization steps required for these orphan drugs; the movement disorder specialists and child neurologists who write the prescriptions; and insurance reimbursement approvals that make these high-cost medications affordable enough for patients to actually receive them.
Who depends on this company?
Parkinson's disease psychosis patients have no other FDA-approved treatment if NUPLAZID becomes unavailable. Rett syndrome patients rely on continuous access to DAYBUE to maintain motor and cognitive function, and interruption means no approved fallback exists. Specialty movement disorder clinics have built their treatment protocols around NUPLAZID as the only approved option, and pediatric neurologists treating Rett syndrome have no comparable approved alternative to turn to if DAYBUE access is cut off.
How does this company scale?
Clinical trial processes and regulatory paperwork for new pipeline drugs can be standardized and reused across multiple programs as the company expands its CNS research — that part gets more efficient over time. What does not get easier is manufacturing. Each drug requires specialized production expertise, and getting a new factory approved by the FDA takes multiple years and cannot be sped up simply by spending more money.
What external forces can significantly affect this company?
Medicare Part D coverage decisions directly control whether elderly and disabled patients can afford NUPLAZID and DAYBUE, making federal reimbursement policy a major force on actual revenue. FDA post-market drug safety monitoring could impose new restrictions on either CNS drug if new side-effect signals emerge after approval. For any future international expansion, the European Medicines Agency has its own separate requirements for orphan neurological therapies that do not automatically follow from FDA approval.
Where is this company structurally vulnerable?
If the FDA withdrew or heavily restricted the approval for either NUPLAZID or DAYBUE — for example, after detecting a serious safety signal through post-market surveillance of CNS side effects — the legal condition that makes each drug the only option would disappear. The forced prescribing channel that drives all revenue would collapse with it. The same would happen if a competing molecule received FDA approval for the same condition, ending the category-of-one status.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph